Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures

Epilepsy Research

Volumn 96, Issue 1-2, 2011, Pages 132-139

  Perucca, E ^a   Elger, C ^b   Halasz P ^c   Falcao A ^d,e   Almeida, L ^f   Soares da Silva, P ^g,h  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BONN   (Germany)

^c NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^d Health Consulting   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSITY OF AVEIRO   (Portugal)

^g DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^h University of Porto   (Portugal)

Author keywords

Antiepileptic drugs; Eslicarbazepine acetate; Partial onset seizures; Pharmacokinetics; Steady state

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ESLICARBAZEPINE; ESLICARBAZEPINE ACETATE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LICARBAZEPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PARTIAL ONSET SEIZURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; STEADY STATE;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; DIBENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; SEIZURES; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 80052837786     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.05.013     Document Type: Article

References (21)

1. Almeida L., Bialer M., Soares-da-Silva P. Eslicarbazepine acetate. The Treatment of Epilepsy 2009, 485-498. Blackwell Publishing, Oxford. S. Shorvon, E. Perucca, J. Engel (Eds.).
2. Almeida L., Falcao A., Maia J., Mazur D., Gellert M., Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J. Clin. Pharmacol. 2005, 45:1062-1066.
3. Almeida L., Minciu I., Nunes T., Butoianu N., Falcao A., Magureanu S.A., Soares-da-Silva P. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J. Clin. Pharmacol. 2008, 48:966-977.
4. Almeida L., Nunes T., Sicard E., Rocha J.F., Falcao A., Brunet J.S., Lefebvre M., Soares-da-Silva P. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol. Scand. 2010, 121:257-264.
5. Almeida L., Potgieter J.H., Maia J., Potgieter M.A., Mota F., Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur. J. Clin. Pharmacol. 2008, 64:267-273.
6. Almeida L., Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J. Clin. Pharmacol. 2004, 44:906-918.
7. Ben-Menachem E., Gabbai A.A., Hufnagel A., Maia J., Almeida L., Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010, 89:278-285.
8. Benes J., Parada A., Figueiredo A.A., Alves P.C., Freitas A.P., Learmonth D.A., Cunha R.A., Garrett J., Soares-da-Silva P. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J. Med. Chem. 1999, 42:2582-2587.
9. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin. Investig. Drugs 2006, 15:637-647.
10. Elger C., Halasz P., Maia J., Almeida L., Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009, 50:454-463.
11. Falcao A., Maia J., Almeida L., Mazur D., Gellert M., Soares-da-Silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm. Drug Dispos. 2007, 28:249-256.
12. Fontes-Ribeiro C., Macedo T., Nunes T., Neta C., Vasconcelos T., Cerdeira R., Lima R., Rocha J.F., Falcao A., Almeida L., Soares-da-Silva P. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R. D. 2008, 9:447-454.
13. Fuseau E., Fabre M.A., Falcao A., Maia J., Almeida L., Soares-da-Silva P. Population pharmacokinetics of eslicarbazepine acetate in adult patients with refractory partial seizures. Epilepsia 2008, 49:432-1432.
14. Gil-Nagel A., Lopes-Lima J., Almeida L., Maia J., Soares-da-Silva P. Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol. Scand. 2009, 120:281-287.
15. Halasz P., Cramer J.A., Hodoba D., Czlonkowska A., Guekht A., Maia J., Elger C., Almeida L., Soares-da-Silva P. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010, 51:1963-1969.
16. Loureiro A.I., Fernandes-Lopes C., Bonifácio M.J., Wright L.C., Soares-da-Silva P. Hepatic UDP-glucuronosyltransferases responsible for eslicarbazepine glucuronidation. Proceedings of the Annual Meeting of the Portuguese Pharmacological Society 2008.
17. Maia J., Almeida L., Falcão A., Soares E., Mota F., Potgieter J.H., Potgieter M.A., Soares-da-Silva P. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int. J. Clin. Pharmacol. Ther. 2008, 46:119-130.
18. Nunes T., Sicard E., Almeida L., Falcao A., Rocha J.F., Brunet J.S., Lefebvre M., Soares-da-Silva P. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr. Med. Res. Opin. 2010, 26:1355-1362.
19. Perucca E., Falcao A., Maia J., Almeida L., Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with epilepsy: pharmacokinetics of eslicarbazepine acetate at steady-state in adults with epilepsy. Epilepsia 2009, 50:196-1196.
20. Vaz-da-Silva M., Almeida L., Falcao A., Soares E., Maia J., Nunes T., Soares-da-Silva P. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin. Ther. 2010, 32:179-192.
21. Vaz-da-Silva M., Nunes T., Soares E., Rocha J.F., Tavares S., Falcão A., Almeida L., Soares-da-Silva P. Eslicarbazepine acetate pharmacokinetics after single and repeated doses in healthy subjects. Epilepsia 2005, 46:191. (abstract).